These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 23941761

  • 1. Effects of phosphate binder therapy on vascular stiffness in early-stage chronic kidney disease.
    Seifert ME, de las Fuentes L, Rothstein M, Dietzen DJ, Bierhals AJ, Cheng SC, Ross W, Windus D, Dávila-Román VG, Hruska KA.
    Am J Nephrol; 2013; 38(2):158-67. PubMed ID: 23941761
    [Abstract] [Full Text] [Related]

  • 2. CKD-induced wingless/integration1 inhibitors and phosphorus cause the CKD-mineral and bone disorder.
    Fang Y, Ginsberg C, Seifert M, Agapova O, Sugatani T, Register TC, Freedman BI, Monier-Faugere MC, Malluche H, Hruska KA.
    J Am Soc Nephrol; 2014 Aug; 25(8):1760-73. PubMed ID: 24578135
    [Abstract] [Full Text] [Related]

  • 3. Aortic Calcification and Arterial Stiffness Burden in a Chronic Kidney Disease Cohort with High Cardiovascular Risk: Baseline Characteristics of the Impact of Phosphate Reduction On Vascular End-Points in Chronic Kidney Disease Trial.
    Lioufas NM, Pedagogos E, Hawley CM, Pascoe EM, Elder GJ, Badve SV, Valks A, Toussaint ND, on behalf of the IMPROVE-CKD Investigators.
    Am J Nephrol; 2020 Aug; 51(3):201-215. PubMed ID: 32023606
    [Abstract] [Full Text] [Related]

  • 4. A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD).
    Toussaint ND, Pedagogos E, Lioufas NM, Elder GJ, Pascoe EM, Badve SV, Valks A, Block GA, Boudville N, Cameron JD, Campbell KL, Chen SSM, Faull RJ, Holt SG, Jackson D, Jardine MJ, Johnson DW, Kerr PG, Lau KK, Hooi LS, Narayan O, Perkovic V, Polkinghorne KR, Pollock CA, Reidlinger D, Robison L, Smith ER, Walker RJ, Wang AYM, Hawley CM, IMPROVE-CKD Trial Investigators.
    J Am Soc Nephrol; 2020 Nov; 31(11):2653-2666. PubMed ID: 32917784
    [Abstract] [Full Text] [Related]

  • 5. Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction On Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study.
    Lioufas N, Toussaint ND, Pedagogos E, Elder G, Badve SV, Pascoe E, Valks A, Hawley C, IMPROVE-CKD Writing Committee..
    BMJ Open; 2019 Feb 21; 9(2):e024382. PubMed ID: 30796122
    [Abstract] [Full Text] [Related]

  • 6. Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial.
    Ureña-Torres P, Prié D, Keddad K, Preston P, Wilde P, Wan H, Copley JB.
    BMC Nephrol; 2014 May 05; 15():71. PubMed ID: 24885942
    [Abstract] [Full Text] [Related]

  • 7. Examining the effects of uric acid-lowering on markers vascular of calcification and CKD-MBD; A post-hoc analysis of a randomized clinical trial.
    Andrews ES, Perrenoud L, Nowak KL, You Z, Pasch A, Chonchol M, Kendrick J, Jalal D.
    PLoS One; 2018 May 05; 13(10):e0205831. PubMed ID: 30356327
    [Abstract] [Full Text] [Related]

  • 8. Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat?
    Martin KJ, González EA.
    Clin J Am Soc Nephrol; 2011 Feb 05; 6(2):440-6. PubMed ID: 21292848
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Dietary interventions for mineral and bone disorder in people with chronic kidney disease.
    Liu Z, Su G, Guo X, Wu Y, Liu X, Zou C, Zhang L, Yang Q, Xu Y, Ma W.
    Cochrane Database Syst Rev; 2015 Sep 16; 2015(9):CD010350. PubMed ID: 26376110
    [Abstract] [Full Text] [Related]

  • 13. CKD, arterial calcification, atherosclerosis and bone health: Inter-relationships and controversies.
    Reiss AB, Miyawaki N, Moon J, Kasselman LJ, Voloshyna I, D'Avino R, De Leon J.
    Atherosclerosis; 2018 Nov 16; 278():49-59. PubMed ID: 30253289
    [Abstract] [Full Text] [Related]

  • 14. Phosphate handling in CKD-MBD from stage 3 to dialysis and the three strengths of lanthanum carbonate.
    Cozzolino M, Bruschetta E, Cusi D, Montanari E, Giovenzana ME, Galassi A.
    Expert Opin Pharmacother; 2012 Nov 16; 13(16):2337-53. PubMed ID: 23033914
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effects of phosphate binders in moderate CKD.
    Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM, Allison MA, Asplin J, Smits G, Hoofnagle AN, Kooienga L, Thadhani R, Mannstadt M, Wolf M, Chertow GM.
    J Am Soc Nephrol; 2012 Aug 16; 23(8):1407-15. PubMed ID: 22822075
    [Abstract] [Full Text] [Related]

  • 17. Is serum sclerostin a marker of atherosclerosis in patients with chronic kidney disease-mineral and bone disorder?
    Figurek A, Spasovski G.
    Int Urol Nephrol; 2018 Oct 16; 50(10):1863-1870. PubMed ID: 30030677
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effect of lanthanum carbonate on serum calciprotein particles in patients with stage 3-4 CKD-results from a placebo-controlled randomized trial.
    Tiong MK, Smith ER, Pascoe EM, Elder GJ, Lioufas NM, Pedagogos E, Hawley CM, Valks A, Holt SG, Hewitson TD, Toussaint ND.
    Nephrol Dial Transplant; 2023 Feb 13; 38(2):344-351. PubMed ID: 35212735
    [Abstract] [Full Text] [Related]

  • 20. Progression of arterial stiffness is associated with changes in bone mineral markers in advanced CKD.
    Krishnasamy R, Tan SJ, Hawley CM, Johnson DW, Stanton T, Lee K, Mudge DW, Campbell S, Elder GJ, Toussaint ND, Isbel NM.
    BMC Nephrol; 2017 Sep 04; 18(1):281. PubMed ID: 28870151
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.